- Fapon Biotech COVID-19 Testing Raw Materials Experimentally Proved to Be Effective on Omicron Variant Detection
- Mr Roc Cui, appointed as the chairman of the IVD Upstream Raw Material and Part Committee of Clinical Industry of National Health Industry Enterprise Management Association
- Satellite conference to showcase powerful COVID-19 Neutralizing Antibody Test Solution for the evaluation of vaccine effectiveness and human immune system response
- Brand refresh to symbolizes the company resolve to enable Disease Identification Earlier, More Accurate, Convenient and Affordable
(Dongguan, China, March 29, 2021) Fapon Biotech brought multiple blockbuster moments at the 18th China Association of Clinical Laboratory Practice Expo (CACLP). As an important figure of the Chinese IVD industry, Fapon Biotech reinforced its presence in CACLP this year with two booth locations to exhibit the latest COVID-19 technology alongside the new brand identity.
The Chairman of Fapon Biotech, Mr Roc Cui was honourably invited to participate in the grand opening ceremony of CACLP. The establishment of the IVD Upstream Raw Material Group and Part Committee of Clinical Industry of National Health Industry Enterprise Management Association was announced at the event and Mr Roc Cui was appointed as the chairman of the committee.
Mr Roc Cui then delivered a speech based on the topic, ‘Future Anticipation, Thoughts on Organizations and Industry’. He unveiled the market opportunities through the analysis of human society, the Chinese Nation and industry, and underscoring the importance of practising the company value, Future Anticipation to advance the cause of human health.
At the satellite conference held on 28 March, a presentation on the subject of ‘Compatible to Global Application! COVID-19 Neutralizing Antibody (NAb) Quantitative Test Solution for Latex-Enhanced Immunoturbidimetry and CLIA’ was shared by Mr Shuang Dai, the Product Scientist of the Infectious Disease of Fapon Biotech. The research background and application of NAb detection was explicitly introduced to audiences in connection to Fapon Biotech’s patented innovative NAb test solution.
Onsite guests, visitors and media were also impressed by the new brand identity revealed by Fapon Biotech. The company was pleased to have its initial launch of the new brand properties to the domestic market through CACLP, as it is the largest and the most influential expo for IVD and clinical laboratory based in China. This refreshed brand image was created to better reflect on the corporate focus of which enabling Disease Identification Earlier, More Accurate, Convenient and Affordable is the ultimate mission of the company.
The COVID-19 product collection contributed to another highlight of Fapon Biotech’s exhibition. As a mainstream COVID-19 reagent raw materials supplier with a favourable reputation to the global market, many visitors dropped in to discover the latest updates and optimization of the COVID-19 products.
Fapon Biotech’s participation in CACLP had promoted communication and cooperation for the co-response in the post-epidemic era where diagnostic tools for the evaluation of vaccine effectiveness and human immune system response are vital to the healthcare system. Fapon Biotech will continue to pay close attention to the pandemic development and push COVID-19 reagent raw materials and one-stop solutions to promote the progress of COVID-19 diagnosis.